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Membrane proteinRecent controversies associated with the structure of the M2 protein from inﬂuenza A virus and the binding
site of drug molecules amantadine and rimantadine motivated the comparison here of the drug binding to
three viral porins including the M2 proteins from inﬂuenza A and B as well as the viral protein ‘u’ from HIV-1.
While the M2 protein from inﬂuenza B does not normally bind amantadine, chimeras with the M2 protein
from inﬂuenza A show blockage by amantadine. Similarly, Vpu does not normally bind rimantadine, but the
single site mutation A18H converts a non-speciﬁc channel to a selective proton channel that is sensitive to
rimantadine. The comparison of structures and amino acid sequences shows that the membrane protein
sample environment can have a signiﬁcant inﬂuence on the structural result. While a bilayer surface bound
amphipathic helix has been characterized for AM2, such a helix may be possible for BM2 although it has
evaded structural characterization in detergent micelles. A similar amphipathic helix seems less likely for
Vpu. Even though the A18H Vpu mutant forms rimantadine sensitive proton channels, the binding of drug
and its inﬂuence on the protein structure appears to be very different from that for the M2 proteins. Indeed,
drug binding and drug resistance in these viral porins appears to result from a complex set of factors.ld Lab, 1800 E. Paul Dirac Dr.,
+1 850 644 1366.
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Recently, there has been interest in the A18H mutant of Vpu, viral
protein ‘u’ of HIV-1, that induces highly selective H+ conductance not
present in the wild type and that is blocked by rimantadine [1,2]. This
mutation generates theproton-conductance signature sequenceHxxxW
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AM2 conductance is amantadine and rimantadine sensitive, inﬂuenza
BM2 conductance is not [4]. These three proteins have essentially no
sequence homology except for the HxxxWmotif. Here, we compare the
sequences, and what is known about the structures of these three
proteins for the domain responsible for the H+ selective conductance.
We will also discuss mechanisms for drug binding and drug resistance.
Of these three proteins, AM2 has been the subject of numerous
conductance, structural, and computational studies. As with Vpu and
BM2, there are no full-length structures, although for BM2 two
overlapping constructs have been used to develop the ﬁrst full-length
structural model [5]. A variety of membrane mimetic environments
have been used for the structural and functional studies. Most of the
structural efforts have focused on the transmembrane (TM) domain, a
single helix that as a tetramer for AM2andBM2 conducts protons across
the viral membranes, an essential function for the life cycle of the virus
[3,6–9]. Based on detailed conductance studies by Pinto and coworkers
[10], theminimal sequence that accounts for the conductanceproperties
of AM2near neutral pH includes not only the TMhelix, but an additional
sequence following the TMhelix. This latter sequence is knownto forma
bilayer-bound amphipathic helix [11,12]. The drugs, amantadine and
rimantadine, were effective against inﬂuenza A until recently when the
inﬂuenza A strains became dominated by an S31N mutation displaying
drug resistance. A variety of other naturally occurring mutants also
display drug resistance. While there is no direct proton-conductance
function associated with Vpu and HIV-1, the TM domain has been
associatedwith non-speciﬁc ion conductance and the ability to enhance
virion release from infected cells [13–15], such that a chimera of Vpu
including the TMdomain of AM2 appears to function normally in HIV-1
and displays proton selective currents [2,15].
The results discussed here reﬂect data obtained from a variety of
technologies utilizing different membrane mimetic environments for
membrane proteins. These environments have structural, dynamical,
and functional implications that cannot be ignored if the goal is to
describe the native state. Unfortunately, we are not yet able to
characterize membrane proteins in their native membrane environ-
ment, but it is possible to characterize proteins in lipid bilayers, even
liquid crystalline environments. Such environments are similar to
native membranes in many respects, including a well-deﬁned hydro-
phobic thickness, a complex interfacial region, and extreme dielectric
and water concentration gradients. Yet it is important to acknowledge
that synthetic bilayers and othermodelmembrane environmentsmay
fall far short of complex native membranes.
2. Materials and methods
This paper is primarily a review paper; however, there are a few
previously unpublished results that are included and hence this
Materials and methods section.
2.1. Sample preparation
15N-amantadine•HCl was synthesized according to the literature
procedure [16]. 15N-labeled acetonitrile (Isotec, Miamisburg, Ohio) was
used to provide the 15N source. The ﬁnal product was veriﬁed by Mass
and 1H solution NMR spectroscopy. The M2 TM domain peptide, NH2-
Ser22-Ser-Asp-Pro-Leu-Val-Val-Ala-Ala30-Ser-Ile-Ile-Gly-Ile-Leu-
His37-Leu-Ile-Leu40-Trp-Ile-Leu-Asp-Arg-Leu46-COOH, was chemical-
ly synthesized by solid-phase synthesis on an Applied Biosystems 430A
Synthesizer using 15N-labeled FMOC amino acids obtained from Isotec
and Cambridge Isotope Labs (Cambridge, Mass). The peptide was
puriﬁed and characterized as described previously [17].
Oriented samples of the 15N-labeled peptide in hydrated DMPC
bilayers were prepared by ﬁrst co-dissolving M2 TM domain (10 mg)
and DMPC (100 mg) in 5 ml TFE (triﬂuoroethanol). TFE was removed
by rotary evaporation and dried under high vacuum. Fifteenmillilitersof 20 mMCBP (citrate-borate-phosphate) buffer (~37 °C, pH 8.0) with
1 mM EDTA (ethylenediamine tetra-acetic acid) was added to the
dried mixture and shaken at 37 °C. This lipid suspension was bath
sonicated for 10 min intermittently. The sonicated suspension was
loaded into a 3-kDa MW cutoff dialysis bag. The dialysis bag was
placed in 1 L of 20 mMCBP buffer overnight to adjust the pH of theM2
TM domain/DMPC liposomes. For an M2 TM domain sample with
10 mM amantadine, 46.9 mg (250 μmol) amantadine hydrochloride
(Fisher Scientiﬁc, GA) in 5 ml CBP buffer was added to an M2 TM
domain loaded vesicle suspension (20 ml). The suspension was
incubated at room temperature overnight and pelleted in 2.5 h by
ultracentrifugation at 196,000×g. The pH value of the pellet was
inferred from a measurement of the supernatant. The pellet was
agitated at 37 °C for 1 h until ﬂuid. For M2 TM domain studies with
amantadine, proteoliposomes were prepared ﬁrst without amanta-
dine and then amantadine was added to a 1-ml suspension of
liposomes at the desired protein:drug ratio and incubated overnight
before sample preparations. This thick ﬂuid was spread onto 50 glass
slides (5.7×12.0 mm) (Marienfeld Glassware, Lauda-Königshofen,
Germany) and dried in a humidity (70–75% relative humidity)
chamber using an N2 atmosphere. The partially dehydrated slides
were stacked together, inserted into a glass tube, and rehydrated in a
96% relative humidity (saturated K2SO4) chamber at 40 °C for one
week. Finally the glass tube was sealed with wax.
2.2. PISEMA spectroscopy
All PISEMA spectrawere acquired at 600 MHzutilizing low-E probes
at the NHMFL except for the full-length M2 PISEMA spectrum that was
obtained at 400 MHz as described previously [11]. The PISEMA spectra
of the M2 TM domain were obtained with the following parameters:
800 μs cross-polarization contact time, 4 ms acquisition time, 6 s recycle
delay, and 1H decoupling with the SPINAL scheme [18]. Spectra were
typically acquired with 32 t1 increments resulting in total acquisition
times ranging from 6 h to 3 days. All experiments were conducted at
either 30 or 40 °C, well above the gel to liquid crystalline phase
transition for the bilayer systems employed. Spectra were processed
using in-house scripts written for NMRPipe [19]. Processing scripts
included the following: zero ﬁlling of t2 to 1024 points, linear prediction
of t1 to 128 points; exponential multiplication window function for t1
and t2 domains with 164 Hz Lorentzian line broadening to enhance
signal to noise; shifted sine bell curve for both t1 and t2 domains;
Lorentz-to-Gauss window function to reduce linewidths; Fourier
transformation of both t1 and t2 time domains; correction of the 15N–
1H-dipolar coupling dimension by a scaling factor of 0.816 (sin54.7°).
15N-chemical shifts were referenced to liquid ammonia at 0 ppm via a
saturated solution of 15NH4NO3 at 26 ppm.
3. Results and discussion
3.1. Sequence analysis of viral ion channels
All three proteins are single pass membrane proteins with a TM
domain ﬂanked by hydrophilic domains (Fig. 1). The focus here will be
on the TM helix and the subsequent amphipathic sequence. With the
exception of a few key functional residues lining the channel pore,
amino acid composition of the TM helices is largely hydrophobic. For
such a composition, the possibilities for hydrogen bonds and
electrostatic contacts at the helix–helix interface are rare. TM helical
association is therefore largely determined by weak van der Waals
interactions. In fact, stronger inter-helical interactions might consid-
erably hinder the dynamics important for channel function. The
amphipathic sequence has a net positive charge and its amphipathic
composition suggests a helical structure.
The TM domains of AM2 and BM2 feature the proton channel
signature sequence, HxxxW [3]. Otherwise, the TM sequences of AM2
Fig. 1. N-terminal sequences of AM2 (Udorn/72), BM2 (Lee/40), and Vpu (HIV-1 isolate HTLVIIIB) extended membrane domains. The italicized residues in BM2 and Vpu are from
AM2 and the histidine and tryptophan residues in the HxxxW are highlighted in red.
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TM domains function to transport protons. Sequence determinants for
oligomeric assemblies of membrane proteins have been recognized as
having helical repeat motifs, such as AxxxG, GxxxG, SxxxS, and
GxxxGxxG, composed of small residues at every fourth or seventh
position, which allow for tight packing at helical interfaces [20]. Such
packing generates the potential of CαH hydrogen bonding and
signiﬁcant inter-helical electrostatic interactions to complement the
non-speciﬁc van derWaals interactions [20]. Both AM2 and BM2 have
sequences characteristic of oligomeric proteins and yet alanine and
glycine residues in the AxxxG sequence of AM2 are not at the helix–
helix interface. Similarly, the SxxSxxxS sequence of BM2 places three
serine residues in a narrow 60° arc of a helical wheel and are not
positioned at the helix–helix interface, but rather they line the
aqueous pore [5,21]. Consequently, the lipid facing and helix
interfacial residues are typically bulky hydrophobic residues such as
valine, leucine, and isoleucine, implying relatively poor stability for
the tetrameric TM domain. Indeed, the plasticity of the AM2 TM
domain has been extensively discussed in the literature [22] and in a
detergent environment this tetrameric structure is not stable enough
for a solution NMR structural characterization. [23]
For Vpu, an AxxAxxxAxxxA sequence places four alanine residues in
an80° arc of ahelicalwheel, and ifwe assume that theTrp22Cα faces theFig. 2. Comparison of the amphipathic drugs, amantadine (A) and rimantadine (B), with the
BM2 structures are represented by only 3 of the 4 helices so that a view into the pore can be
amino group of the drugs is colored blue, the AM2 drug binding site is primarily hydrophobic
red.pore (as the corresponding tryptophan residues do in AM2 and BM2),
then the Ala residues are not facing into the pore but are largely at the
helix–helix interface. This may explain why the Vpu TM domain
oligomeric structure is more stable even in a detergent environment
than theAM2TMdomain [24]. The stabilityof theVpuTMdomain is also
seen in bicelle spectra where the NMR linewidths are much narrower
than the line widths observed for the AM2 TM domain in bilayers [25].
The pore of Vpu is very hydrophobic with only 4 hydrophilic residues
(i.e. 4 Trp22 residues, assuming that it is tetrameric and that tryptophan
is considered hydrophilic), while AM2 has 12 hydrophilic residues and
BM2has20 such residuesper tetramer. BM2andVpuarenot sensitive to
the channel blocking drugs, amantadine and rimantadine, while the
AM2 conductance is effectively blocked by amantadine, which binds
with high afﬁnity and induces a signiﬁcant structural change to the
protein [10,26,27]. Interestingly, the A18H mutation converts Vpu to a
highly selective proton channel that has amantadine sensitivity and also
doubles the number of hydrophilic residues facing the pore [25]. BM2
can also be made amantadine sensitive by forming a chimera in which
the N-terminal half of the TM helix is replaced with the corresponding
sequence from AM2 (Fig. 1) [28]. This chimera decreases the number of
hydrophilic residues in the BM2 TM domain from 20 to 12. Con-
sequently, it appears that amantadine binding requires a balance
between hydrophilic and hydrophobic residues in the pore (Fig. 2).pores from AM2 (C, PDB 2H95) and BM2 (D, PDB 2KIX) on the same scale. The AM2 and
achieved. Furthermore, only residues Leu26-Ile42 (AM2 numbering) are displayed. The
indicated by green (left) while BM2 (right) channel pore is lined with polar residues in
Fig. 3.Overlay of solution NMRHSQC spectra of the AM2 conductance domain (residues
22–62) (blue) and the full-length protein (red) in LPPG micelles at pH 4. The
conductance domain of AM2 folds independently of other domains, thus providing the
basis for the divide-and-conquer approach for characterizing viral ion channels
structures.
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with a primary amine and consequently it is not surprising that
increased hydrophilicity in BM2 could inhibit drug binding.
For AM2, the conductance properties of the full-length protein are
nearly identical (at least at neutral pH) to the TM domain if the
additional residues of the amphipathic sequence are included [10].
Consequently, we refer to constructs for AM2 that include residues
22–62 or 18–60 as the ‘conductance domain’. The sequence following
the TM helix in each of these proteins displays a preponderance of
positively charges residues (Fig. 1). Within the 19 residues following
the key tryptophan residue (Trp41 in AM2, Trp23 in BM2 and Trp22 in
Vpu), each of these proteins has 6 positive charges (assuming
histidine is counted as a positive charge). The 19-residue sequences
have a net positive charge of 4 for AM2 and Vpu and a net positive
charge of 6 for BM2. This is consistent with the positive inside rule and
presumably reﬂecting interactions between the protein and the
negatively charged lipids on the viral interior.
3.2. Structural perspective
These viral porins provide some of the best examples of the
‘divide-and-conquer’ strategy [29,30] for the structural characteriza-
tion of membrane proteins, in which individual functional domains
are separately studied. The usefulness of this approach for these
proteins is partly due to the fact that these proteins have identiﬁable
functional domains. Substantiated with functional assays, this
strategy can help overcome challenges associated with spectroscopy
and crystallography studies of full-length membrane proteins. The
structures of isolated domains of BM2, Vpu, and AM2 have provided
signiﬁcant insights into the structures and functions of the full-length
proteins [31–35]. As an example, solution NMR HSQC spectra of the
full-length and conductance domains of AM2 are compared in Fig. 3.
The near perfect overlap of these two spectra and the appropriate
dispersion of resonances for a largely helical protein are yet another
justiﬁcation that this divide-and-conquer approach is an effective and
useful strategy for the structural characterization of such proteins
with deﬁnable functional domains.
3.2.1. The transmembrane domain
Two drug binding sites have been proposed for inﬂuenza A M2,
one distal to the HxxxWmotif in the N-terminal half of the pore based
on TM domain studies,[26,36–39] and the other proximal to this motif
on the lipidic face of the TM helices based on solution NMR studies of
the longer conductance domain (Fig. 4) [23]. In addition, these two
binding sites differ in their time-averaged orientation for the
amantadine C-N bond: being approximately parallel to the bilayer
normal for the pore binding site and approximately perpendicular to
the bilayer normal for the lipid/M2 interfacial site. Amantadine and
rimantadine belong to a class of amphiphilic drugs with high afﬁnity
for themembrane interfacial region, with partition coefﬁcients as high
as ~37 in POPC lipid bilayers measured by solution NMR diffusion
experiments [40]. Solid-state NMR, neutron diffraction, andmolecular
dynamics simulations have reported similar results [41].
The debate over which drug binding site is biologically relevant
appears to have been resolved with the recent measurement of
distances between amantadine and the TM domain by Cady and
coworkers using solid-state NMR where they identiﬁed the high
afﬁnity site as the pore binding site and the lipid interface site as a low
afﬁnity site [37]. In addition, functional studies of mutants have
provided convincing evidence [42] and we have also obtained data on
amantadine binding to the AM2 TM domain by isotopically labeling
the amino group of amantadine with 15N and by using 15N-Leu-
labeled AM2 TM domain through a series of 15N cross-polarization
experiments with different peptide to amantadine ratios in DMPC
liquid crystalline lipid bilayers. Fig. 5 shows the spectra of 15N-labeled
amantadine with and without the 15N-labeled AM2 TM domain. All ofthe spectra were obtained from samples at pH 8.0 and 30 °C. The
spectrum of amantadine in (unoriented) liposomes (Fig. 5A) shows a
typical powder pattern for an 15NH2 group. As we have shown
previously the hydrocarbon portion of this drug is buried in the
hydrophobic core of the bilayer, while the amino group interacts with
the interfacial region of the lipid bilayer, with the C-N vector pointing
away from the middle of the bilayer [40,41]. In Fig. 5B the spectrum of
the same sample uniformly aligned with the bilayer normal parallel to
the magnetic ﬁeld is shown. Here, in the lipid environment the
amantadine resonance aligns with the δ|| edge of the powder pattern
indicating that the time-averaged orientation of the C-N bond in
amantadine is parallel to the bilayer normal, in agreement with
molecular dynamics simulations [41]. Upon the addition of the AM2
TM domain in a ratio of 8 drug molecules per tetramer the time-
averaged alignment for amantadine is still parallel with the bilayer
normal (Fig. 5C) as expected for the pore binding site, but not the
lipid/M2 interfacial site. In the former case ~12.5% of the drug
molecules are bound to the pore, which would have the C-N bond
approximately parallel to the bilayer normal and in the latter case
~50% of the drug molecules would be bound to the protein and have
their C-N bond perpendicular to the bilayer normal, resulting in 50% of
the amantadine 15N signal near δ⊥. In this sample, most of the
amantadine signal is from lipid bilayer bond amantadine as in Fig. 5B.
The narrow AM2 TM domain signals clearly show that the protein is
bound with amantadine, as the resonances are between 192 and
214 ppm. The unbound protein has very broad resonances between
Fig. 4. Comparison of the two drug binding sites described for M2 proteins. (A) Rimantadine binding site in the conductance domain of AM2 based on the solution NMR structure
in DHPC micelles. The drug is near the bilayer interfacial region interacting with the lipid and a hydrophobic pocket on the external structure of the protein (PDB 2RLF) [23].
(B) Amantadine modeled into the pore of the TM domain of AM2 (based on data used for PDB 2H95) [26,37,38].
Fig. 5. 15N static spectra by cross-polarization of (A) randomly oriented bilayer sample
with amantadine; (B) uniformly aligned sample of (A); (C) uniformly aligned bilayer
sample with 5-site 15N leucine-labeled AM2-TM domain, at a 1:8 molar ratio of M2 TM
domain to amantadine; (D) a sample similar to (C) but with a 1:1 molar ratio; (E) a
sample similar to (C) but without amantadine. All the samples were prepared at pH 8.0
in DMPC bilayers; the oriented sample was uniformly aligned with the bilayer normal
parallel to the static magnetic ﬁeld.
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near the δ⊥ edge of the powder pattern, which could either indicate a
small amount of amantadine bound to the alternative AM2 binding
site or a small amount of unoriented material in the sample (a
situation that is common). When the molar ratio is reduced to 1:1 for
the tetramer (Fig. 5D) the only amantadine signal is at δ|| once again
indicating that amantadine is in the pore binding site. At this
stoichiometry if binding were occurring at the lipid/protein interface
not only would we observe a different amantadine 15N frequency
(close to δ∞), but we should see a break in the four fold symmetry of
the TM domain resonances (since on average there would be 1
amantadine-bound M2 monomer to 3 unbound monomers); neither
of which is observed. Indeed, almost all of the AM2 TM domain signal
is in the form of the bound state, an indication that the stoichiometry
for amantadine binding is 1:1 and clearly far removed from the 1:4
stoichiometry that would be required for the alternative binding site.
A ﬁnal note on these spectra is that the amantadine in the pore
binding site is undergoing considerable dynamics although the time-
averaged C-N bond is parallel to the bilayer normal. This is consistent
with NMR observations that the symmetry of the tetramer is not
broken by amantadine binding [26] as would be expected if the amino
group were bound to a single helix, instead such interactions appear
to be extensively averaged over all four helices. This result is also
consistent with the molecular dynamics simulations that show rapid
dynamics for bound amantadine and its alternating interactions with
the four helices [43]. Therefore, we conclude that the stoichiometry of
amantadine binding is one drug molecule per tetramer. Furthermore,
the orientation of the drug in the bound state is such that the time-
averaged orientation of the C-N bond is approximately parallel to the
bilayer normal. These results conﬁrm those of Cady et al. [37] in
characterizing the pore binding site as the high afﬁnity site, while not
eliminating the possibility of a weak binding site at the lipidic
interface. Interestingly, molecular dynamics simulations indicate that
the C-N vector points toward the bulk water while bound in a lipid
bilayer [41] but toward the middle of the bilayer while bound to the
pore of the AM2 TM domain [38].
There is little doubt that Schnell and Chou [23] observed a binding
site for rimantadine on the exterior of the tetramer just as there is
little doubt that rimantadine was not binding in the pore. This
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environment, which does not have a well-deﬁned hydrophobic
thickness, unlike a lipid bilayer. Consequently, it is possible to have
helices packed in a tight bundle with only a small helix tilt angle with
respect to the bundle axis in micelles while in bilayers the lengthy
hydrophobic helix is forced to tilt with respect to the bilayer normal
[12,44]. As a result there is no cavity in the pore of adequate size to
accommodate the drug in DHPC micelles. The other structures of the
AM2 TM domain all have considerably larger helical tilt angles and all
display cavities appropriate for amantadine binding in the pore. In the
recent structure of the BM2 TM domain [5] where the hydrophobic
sequence is even longer than that in AM2, the solution NMR structure
suggests an alternative mechanism by which the pore can be closed
and amantadine access prevented; the formation of a coiled-coil
structure resulting in tight packing of the helices [5]. The overall
conclusion is that in addition to having an appropriate hydrophilic/
hydrophobic environment in the pore for amantadine binding it is
also necessary to have a substantial tilt of the helices to open a cavity
large enough for the drug. Some of the naturally occurring
amantadine-resistant mutants may function to impede drug binding
by reducing the size of the cavity, such as S31N and A30T [38].
In order to further investigate the binding site of amantadine inM2
channels, we preparedmutants of the AM2 TM domain corresponding
to the naturally occurring drug-resistant mutations, V27S, V27A,
A30T, and S31N. As we noted above, spectra of aligned AM2 samples
are very sensitive to amantadine binding; as a result, a direct inference
about drug binding can be made by comparing spectra in the absence
and presence of amantadine. Fig. 6 shows that the PISEMA spectra of 5
15N-labeled leucine residues in the M2 TM domain do not change
signiﬁcantly in the presence (red) or absence (black) of amantadine
for the S31N, V27A, and A30Tmutants. These data suggest that the TM
domain is functioning similarly to the full-length protein; i.e., the TM
domain mutants confer drug resistance by eliminating amantadine
binding. We have already suggested that this may be due to the
increased hydrophilicity in these constructs. Note that in AM2, A30
and V27 correspond to sites in BM2 that have serine residues
supporting the argument that increased hydrophilicity decreases
amantadine binding. For V27S a different result is observed, in which
amantadine clearly binds to the tetramer and furthermore the amide
resonance frequencies for the bound state are very similar to those of
the wild type (Fig. 7), suggesting that the backbone structural changes
induced by the V27S mutations are minimal, both in the presence and
absence of amantadine. Previously, Astrahan and coworkers [45]Fig. 6. PISEMA spectra of 5-site 15N Leu-labeled amantadine-resistant mutants of AM2 TM dusing surface plasmon resonance also observed that some amanta-
dine-resistant M2 TM domain mutants bind amantadine. So far the
V27S mutation has been assayed for drug sensitive proton conduc-
tance using the full-length protein [46] while drug binding (shown
here) has been assessed using the TM domain, so there is the
possibility that the full-length protein does not bind amantadine and
therefore, the possibility exists that for this mutant the TM domain
maybe a poor model for the full-length protein with regard to drug
binding. We have suggested above that amantadine resistancemay be
caused by increased hydrophilicity in the pore or a decrease in the size
of the binding cavity. Now we see that V27S binds amantadine while
V27A does not. In addition, the BM2 chimera that binds amantadine
includes S9V (residue 27 in AM2) and WT BM2 with Ser9 does not
bind amantadine. Hence, the mechanisms governing amantadine
binding and resistance are complex, apparently with multiple
mechanisms at play for achieving amantadine resistance and the
prevention of amantadine binding.
The A18Hmutation converts Vpu from a non-selective channel to a
highly selective H+ channel that is sensitive to rimantadine. In both
micelle and bicelle samples, the structurally characterized TM helix
length is increased by this mutation and consequently the helical tilt
increases from 30° to 41° [25].While it is tempting to assume that Vpu
functions like the AM2 tetramer, the binding of rimantadine in the
pore of the Vpu TM domain induces only modest changes in the
anisotropic chemical shifts and 15N-1H dipolar couplings (less than
1 ppm and less than 0.1 kHz, respectively, except for His18, the
counterpart to His37 in AM2). These minimal changes in frequency
mean that there is no change in helix tilt and essentially no change in
backbone structure upon rimantadine binding. In contrast, AM2 TM
domain displays signiﬁcant changes in the C-terminal half of the TM
helix, including changes in the anisotropic chemical shifts and dipolar
interactions of 30 ppm and 3 kHz, respectively, resulting in a
substantial change in helix tilt from 31° to 20° [26]. As an aside, Vpu
TM domain data were obtained from bicelles and therefore for a
comparison to the aligned bilayers the range of spin interaction
changes should be doubled. Clearly, the drug binding mechanisms for
AM2 and Vpu are very different. Potentially, the increased stability of
the Vpu TM domain tetramer is due to the numerous small residues
being at the helix–helix interface resulting in a structure that is not
susceptible to the inﬂuence of drug binding. In addition, the lack of a
glycine residue (Gly34 in AM2, which is Ile15 in Vpu) would also
hinder the formation of a kink in the TM helix. The greatest inﬂuence
by rimantadine on the Vpu TM domain resonances is at His18,omain with (red) and without amantadine (black). (A) A30T; (B) S31N; and (C) V27A.
Fig. 7. PISEMA spectra of the V27S mutant. (A) Comparison of V27S with and without amantadine; 2-site 15N Ile (33, 42 )-labeled V27S mutant of AM2 TM domain with (blue) and
without (red) amantadine. (B) Comparison of V27S and WT AM2 in the presence of amantadine; 2-site 15N Ile V27S AM2 TM domain with amantadine (blue—as in panel A)
superimposed with 5 site 15N Ile (32, 33, 35, 39, 42) WT AM2 TM domain with amantadine (red).
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contrary to the situation in AM2, where the amantadine binding
cavity is well removed from His37.
3.2.2. The positively charged sequence
Apart from TM domains, amphipathic helices are common motifs
encountered inmembraneproteins even though there are exceptionally
few amphipathic helical structures interacting with lipid bilayers
deposited into the PDB. The clustering of polar and hydrophobic
residues on opposite faces of helices provides domains that can
simultaneously interact with polar head groups as well as the
hydrocarbon core of the lipid bilayer. Due to this bimodal interactionFig. 8. PISEMA spectra of 15N Phe-labeled full-length M2 protein in DMPC:DMPG (4:1) bilaye
superimposed.with the membrane interior and aqueous environment, amphipathic
helices can have a major role in membrane protein stability and
function. They have also been implicated in membrane localization,
curvature sensing, and interaction with soluble proteins. Despite the
signiﬁcance of the amphipathic helix motif, the scarcity of these
structures may be due to the sensitivity of these helices to surface
charge, surface curvature, and numerous other details of themembrane
interfacial region, all ofwhich combine tomake amphipathic helices one
of themost challenging aspects of membrane protein structure biology.
Spectra of uniformly 15N-labeled and 15N Phe (Fig. 8)-labeled full-
length AM2 protein reconstituted in DMPC:DMPG bilayers provides
convincing evidence for a bilayer surface bound helix betweenrs. A simulated PISA wheel for a helix tilted at 100° with respect to the bilayer normal is
545M. Sharma et al. / Biochimica et Biophysica Acta 1808 (2011) 538–546residues 47 and 55 [11,47]. This sequence includes four of the ﬁve
phenylalanine residues in the full-length protein. The PISEMA
spectrum [11] shows that all but one of the resonances is in the
vicinity of a helical wheel characterized by a 100° tilt with respect to
the bilayer normal. The importance of 100° versus 80° tilt is that the C-
terminus (with carbonyl oxygens not involved in helical hydrogen
bonds) is more exposed to the bilayer surface at 100° vs. 80°.
Furthermore, the resonances of the hydrophobic portion of this wheel
showed resistance to deuterium amide exchange after prolonged
exposure indicating that these residues are deeply buried in the
hydrocarbon core of the bilayer [11]. However, in the recent solution
NMR structure of the AM2 conductance domain in DHPC micelles,
these helices formed a water soluble tetrameric bundle that showed
no hindrance to H/D exchange [23]. We suspect that this is due to the
inability of the detergent micelle environment to provide a suitable
model of the amphipathic bilayer surface for these helices or that
monomeric detergents have stabilized a water soluble tetramer
bundle of this amphipathic helix.
The DHPC micelle solution structure of the BM2 TM domain
(residues 1–33) features a TM helix through residue Gln30 [5]. The
solution NMR structure of BM2 residues 26–109 anchored to LMPG
micelles provides a helical structure for residues 44–103 and
consequently most of the post-TM sequence that has a net positive
charge (residues 26–41) is not structurally deﬁned in these samples
[5]. While a hypothetical helical wheel for BM2 residues 28–41
suggests an amphipathic helix, the fraction of the wheel that is
hydrophobic is less than that for AM2 with two lysines, K32 and K38,
penetrating into the hydrophobic surface and thereby requiring these
residues to snorkel to the hydrophilic region of the bilayer interface
[48,49]. A cluster of hydrophobic residues, Leu28, Ile31, Val35, and
Ile39, make an arc of 80° on the helical wheel (with Lys 32 and Lys 38
the arc would extend to 120°). In addition, this hydrophobic surface
appears to be a continuation of the lipid facing hydrophobic surface of
the TM helix, and therefore, we would anticipate that this region
forms a very similar structure to that of AM2 [11] with the exception
that the amphipathic helix may not be so buried in the hydrophobic
region of the bilayer. While this region was not structured in the
solution NMR structure, detergent sample preparation was required
to solubilize this domain in the 26–109 construct, it is possible that in
bilayer preparations this region could be helical and associated with
the bilayer interface.
As with AM2 and BM2, Vpu appears to form a weak amphipathic
helix between residues Ile26 and Gln35 where Ile25 or Ile26 appear to
be the end of the TM helix [25]. The amphipathic sequence is less than
three turns in length and has a net charge of only +2. Consequently,
the argument for a post-TM amphipathic helix is weakest for Vpu,
consistent with the overall structural and functional features of this
channel suggesting that it is very different from AM2 and BM2.
4. Conclusions
These three viral porins have relatively short sequences and
perform multiple viral functions. While AM2 and BM2 form proton
channels, wild-type Vpu has no such speciﬁcity, but with a single site
mutation, A18H, it forms proton speciﬁc channels that are sensitive to
rimantadine. Consequently, the focus of this paper was on the
structural comparison of these three viral porins. The ‘divide-and-
conquer’ approach for the viral porins with multiple functional
domains has been very successful for studies of the transmembrane
and conductance domains of M2 and Vpu. However, through these
studies a sensitivity to the protein's environment has been demon-
strated, especially for M2. The helical interface for M2 is composed of
large hydrophobic side chains with few opportunities for speciﬁc
interactions to stabilize the helical bundle, while a portion of the Vpu
helical interface is composed of alanine residues leading to a more
stable helical complex. Consequently, the structural dependence onthe protein environment has been more signiﬁcant for M2 than for
Vpu. Importantly these comparisons once again, emphasize that
membrane protein structures are determined not just by their amino
acid sequences and their intra-protein interactions, but also by their
environments and the protein's interactions with their environments,
as recognized by Christian Anﬁnsen [50].
In the A18H mutant of Vpu the TM helix tilt appears to be greater
than for AM2 and, while rimantadine binds, the mechanism by which
it binds appears to be very different from that for AM2, where drug
binding induces a helix kink and much more signiﬁcant shifts in the
PISEMA resonances. The recent debate over the biologically relevant
drug binding site in AM2 appears to have been resolved by the
measurement of distances to the drug [37] but also by our
characterization of the drug:tetramer stoichiometry of 1:1 and drug
orientation in the binding site. What is apparently far more complex is
themechanism bywhichmutations induce drug resistance; indeed, in
M2 there may be a mix of steric, chemical, hydrophobic, and dynamic
inﬂuences that result in such resistance.Acknowledgments
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